مقالوصول مفتوح2026
Dermatology Reports
Chronic skin diseases such as psoriasis, vitiligo, eczema, and acne can have substantial psychosocial effects beyond physical symptoms. Visible dermatological conditions often lead to stigmatization, which may negatively influence social interactions, emotional well-being, and quality of life. However, limited research has examined perceived stigmatization among patients with chronic skin diseases in the Eastern Province of Saudi Arabia. This study aimed to quantify and compare perceived stigmatization among patients with chronic skin diseases and identify demographic and clinical factors associated with stigma severity. A cross-sectional study was conducted among 446 patients with chronic skin diseases. Data were collected using a structured questionnaire, including sociodemographic characteristics, clinical information, and the 6-Item Stigmatization Scale. Descriptive statistics were used to summarize participant characteristics. Independent t-tests, one-way analysis of variance (ANOVA), and multivariable linear regression analysis were performed to examine associations between stigma scores and demographic and clinical variables. A total of 446 participants were included, with females comprising 264 (59.2%) and most aged 18-40 years (291, 65.2%). Vitiligo (114, 25.6%) and psoriasis (102, 22.9%) were the most common conditions. Many participants reported stigma-related experiences, including feeling unattractive sometimes or very often (326, 73.0%). Stigma scores were significantly higher among males than females (8.12±3.93 vs. 7.03±4.73, p=0.011) and varied by monthly income (p<0.001). Stigma also differed across disease types (p<0.001), with the highest scores among vitiligo patients (8.74±3.98). In regression analysis, gender (B=1.039, p=0.016), age at disease onset (B=0.052, p=0.002), disease duration (B=-1.268, p=0.003), and family history (B=1.825, p<0.001) were significant predictors of stigma. To conclude, stigmatization is a common psychosocial burden among patients with chronic skin diseases. Addressing stigma through patient support, public education, and integrated psychological care may help improve the well-being of affected individuals.
chronic skin diseasepsoriasisvitiligoatopic dermatitis
مقالوصول مفتوح2026
JAAD Case Reports · مجلد 73 · 106-110
Severe combined immunodeficiency (SCID) represents a group of life-threatening primary immunodeficiencies characterized by defective T and B-lymphocyte function, typically presenting with severe and recurrent infections during early infancy.1 A subgroup of them, referred to as radiosensitive SCID, results from defects within the nonhomologous end-joining (NHEJ) pathway, which plays a crucial role in DNA double-strand break repair during V(D)J recombination. The NHEJ1 gene encodes for Cernunnos/XLF, an NHEJ1 scaffolding protein that is vital for DNA end ligation during this form of repair.
vitiligo-like depigmentationsevere combined immunodeficiencynon-homologous end joiningDNA double-strand break repair
مراجعةمفتوح (مستودع)2025
Saudi Medical Horizons Journal · مجلد 5 (1) · 42-49
The main objective of this study was to evaluate and summarize the available clinical evidence on the efficacy and safety of tofacitinib for the treatment of vitiligo. A thorough search across four databases identified 416 relevant publications. After removing duplicates using Rayyan QCRI and assessing their relevance, 204 full-text articles were reviewed, and ultimately, five studies met the criteria for inclusion were included. A total of 121 vitiligo patients were included; less than half of them 52 (43%) were males. Findings indicate that while tofacitinib alone has limited effectiveness, its combination with narrowband-ultraviolet B (NBUVB) phototherapy significantly enhances repigmentation, particularly in refractory cases, including acral lesions. Micro-focused UVB phototherapy also demonstrates high efficacy, with further improvements observed when paired with tofacitinib. However, a 16-week treatment duration may be insufficient for patients with inadequate responses to prior therapies, suggesting the need for higher doses or extended treatment periods. This makes a combination of tofacitinib and phototherapy promising as a therapeutic strategy against vitiligo, with cases resistant to all the modalities of standard therapy. As promising as these results read with significant repigmentation, full optimization of treatment duration and dosage will be imperative. These findings need to be further confirmed in future large, randomized controlled trials and long-term outcomes evaluated to definitely establish a standardized protocol for vitiligo management. These efforts will be essential to fully realize the potential of Janus kinase (JAK) inhibitors as part of a comprehensive, targeted approach to the management of vitiligo.
tofacitinibvitiligoJAK inhibitorsnarrowband UVB phototherapy